Expert Care for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS): Symptoms, Causes, Diagnosis, and Treatment | AIROC Hospitals

About Myelodysplastic Syndrome – Overview and Types

Myelodysplastic syndrome (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells originating in the bone marrow. In MDS, the bone marrow fails to produce enough healthy blood cells, leading to low blood counts that can affect red blood cells, white blood cells, platelets, or a combination of all three. At AIROC Hospitals, our hematology-oncology specialists provide comprehensive diagnostic and treatment services for MDS, with the goal of managing symptoms, reducing complications, and monitoring for disease progression.

MDS is considered a type of blood cancer and can range from a mild condition requiring only monitoring to a more serious disorder with a risk of progressing to acute myeloid leukemia (AML). Because MDS mainly affects older adults and can develop gradually, our team at AIROC Hospitals emphasizes careful classification and individualized care planning.

Types of Myelodysplastic Syndrome

MDS is classified into several subtypes based on the specific blood cell lines affected and the appearance of cells under the microscope:

• MDS with Single Lineage Dysplasia – Affects only one type of blood cell, such as red blood cells.
• MDS with Multilineage Dysplasia – Affects two or more types of blood cells.
• MDS with Ring Sideroblasts – Characterized by abnormal iron deposits within developing red blood cells.
• MDS with Excess Blasts – Involves a higher number of immature blood cells (blasts) in the bone marrow, associated with a higher risk of progressing to leukemia.
• MDS with Isolated del(5q) – A subtype associated with a specific chromosomal abnormality, often with a distinct treatment response.
• Unclassifiable MDS – Cases that do not fit clearly into the categories above.

Accurately identifying the specific subtype and risk category is essential for guiding treatment, and our specialists at AIROC Hospitals use detailed bone marrow evaluation to classify each case precisely.

 

Symptoms and Causes

Common Symptoms of Myelodysplastic Syndrome

Symptoms of MDS relate to low blood cell counts and may include:

• Fatigue and weakness, often due to anemia (low red blood cells)
• Shortness of breath
• Pale skin
• Frequent or unusual infections, related to low white blood cell counts
• Easy bruising or bleeding, related to low platelet counts
• Small red or purple spots on the skin (petechiae)
• Fever
• Unexplained weight loss

Because early MDS can cause mild or no symptoms, it is sometimes discovered incidentally through routine blood tests. Persistent fatigue, frequent infections, or unusual bleeding should be evaluated by a specialist.

Causes and Risk Factors

The exact cause of MDS is not fully understood, and it is generally categorized based on whether a clear cause can be identified:

• Primary (De Novo) MDS: Occurs without a known identifiable cause, which represents the majority of cases.
• Secondary (Treatment-Related) MDS: Develops after previous chemotherapy or radiation therapy for another cancer, and tends to behave more aggressively.
• Age: The most significant risk factor, with MDS most commonly diagnosed in adults over 70.
• Sex: Slightly more common in men than women.
• Exposure to Certain Chemicals: Long-term exposure to benzene and certain industrial chemicals has been linked to increased risk.
• Smoking: Associated with a higher risk of developing MDS.
• Genetic Conditions: Certain inherited bone marrow disorders can increase susceptibility, particularly in younger patients.

Understanding whether MDS is primary or treatment-related helps our team at AIROC Hospitals determine the most appropriate management approach and anticipate disease behavior.

 

Diagnosis and Treatment

How Myelodysplastic Syndrome Is Diagnosed

At AIROC Hospitals, we use a thorough diagnostic approach to confirm MDS and determine its subtype and risk level:

• Complete Blood Count (CBC): Identifies abnormalities in red blood cells, white blood cells, and platelets that may suggest MDS.
• Peripheral Blood Smear: Examines blood cells under a microscope to detect abnormal shapes or immature cells.
• Bone Marrow Biopsy and Aspiration: The key diagnostic test, providing detailed information about the number and appearance of developing blood cells.
• Cytogenetic and Molecular Testing: Identifies chromosomal and genetic abnormalities that help classify MDS and assess risk of progression to leukemia.
• Risk Stratification Scoring: Combines blood counts, bone marrow findings, and genetic information to assess prognosis and guide treatment planning.

Treatment Options at AIROC Hospitals

Treatment for MDS is tailored to the subtype, risk category, symptoms, and the patient's overall health, and may include:

• Watchful Monitoring: For lower-risk MDS with mild or no symptoms, regular monitoring may be recommended before starting active treatment.
• Supportive Care: Includes blood transfusions and growth factor medications to help manage low blood counts and related symptoms.
• Medications to Improve Blood Cell Production: Certain drugs can help stimulate healthier blood cell development in select patients.
• Chemotherapy: Used for higher-risk MDS to help control abnormal blood cell production and reduce the risk of progression to leukemia.
• Targeted Therapy: Directed at specific genetic abnormalities in select MDS subtypes.
• Stem Cell Transplant: The only potentially curative treatment for MDS, involving replacement of the diseased bone marrow with healthy donor stem cells; typically considered for eligible higher-risk or younger patients.
• Infection and Bleeding Prevention: Given the impact on immune function and clotting, proactive management of infection risk and bleeding is an important part of ongoing care.

Our multidisciplinary team at AIROC Hospitals — including hematologists, transplant specialists, and supportive care providers — works together to design a treatment plan that manages symptoms, monitors disease progression, and addresses the risk of leukemia development.

 

Prevention and Risk Factors

Because the exact cause of MDS is often unclear and many risk factors, such as age, cannot be changed, there is currently no established way to prevent it directly. However, the following can support risk reduction and early detection:

• Avoiding Known Chemical Exposures: Limiting long-term exposure to benzene and other industrial chemicals where possible.
• Avoiding Tobacco Use: Reducing smoking-related risk may help lower the likelihood of developing MDS.
• Monitoring After Previous Cancer Treatment: Individuals who have undergone chemotherapy or radiation for another cancer should maintain regular blood count monitoring.
• Awareness of Persistent Symptoms: Ongoing fatigue, unusual bruising, or frequent infections should be evaluated promptly, particularly in older adults.
• Routine Blood Testing: Regular check-ups, including blood counts, can help detect abnormalities early, even before symptoms develop.

At AIROC Hospitals, we emphasize the importance of routine blood monitoring and prompt evaluation of persistent symptoms, as early detection and careful risk classification play a key role in successfully managing myelodysplastic syndrome.

 

This content is intended for informational purposes only and does not substitute professional medical advice. Please consult a specialist at AIROC Hospitals for personalized diagnosis and treatment recommendations.